PD1-04 DETRUSOR INJECTIONS OF ONABOTULINUM TOXIN A (BOTOX®) VERSUS ABOBOTULINUM TOXIN A (DYSPORT®) IN THE MANAGEMENT OF NEUROGENIC DETRUSOR OVERACTIVITY : A CASE CONTROL STUDY

Abstract

Listen

Translate article

You have accessJournal of UrologyUrodynamics/Incontinence/Female Urology: Neurogenic Voiding Dysfunction I1 Apr 2015PD1-04 DETRUSOR INJECTIONS OF ONABOTULINUM TOXIN A (BOTOX®) VERSUS ABOBOTULINUM TOXIN A (DYSPORT®) IN THE MANAGEMENT OF NEUROGENIC DETRUSOR OVERACTIVITY : A CASE CONTROL STUDY Benoit Peyronnet, Castel-Lacanal Evelyne, Roumiguie Mathieu, Marque Philippe, Rischmann Pascal, and Game Xavier Benoit PeyronnetBenoit Peyronnet More articles by this author , Castel-Lacanal EvelyneCastel-Lacanal Evelyne More articles by this author , Roumiguie MathieuRoumiguie Mathieu More articles by this author , Marque PhilippeMarque Philippe More articles by this author , Rischmann PascalRischmann Pascal More articles by this author , and Game XavierGame Xavier More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.199AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Onabotulinumtoxin-A (BOTOX®) is the only botulinum toxin whose use is based on multicenter randomized controlled trials and is therefore the only one to be licensed in the US and Europe for the management of neurogenic detrusor overactivity (NDO). However, the use of abobotulinum-toxin A (Dysport®) for NDO is also supported by high level of evidence studies. Only one small sample case-control study has aimed to compare the results of this two toxins in the management of NDO. Our aim was to compare the outcomes of detrusor injections of onabotulinum toxin A and abobotulinum toxin A in NDO patients. METHODS Data of all consecutive patients who underwent a first detrusor injection of botulinum toxin A for NDO at a single-institution between 2006 and 2014 were prospectively collected. In our department, abobotulinum toxin was the only first-line botulinum toxin used to treat NDO from 2006 to 2011 (first era). From 2011, as onabotulinum-toxin A became licensed in US and Europe, we decided to use it as the first-line botulinum toxin (second era: 2011–2014). Detrusor injections were performed at a dose of 200 U for onabotulinum toxin A and at a dose of 750 U for abobotulinum toxin A. Before and 6 weeks after injection, patients carried out a 3-day bladder diary and had urodynamics. The success was defined as the combination of a cllean intermittent self-catheterisation number under 8 per 24 hours, urgency, urinary incontinence and detrusor overactivity relief. Perioperative parameters were compared between the onabotulinum and abobotulinum toxin A groups. RESULTS Two-hundred and eleven patients were included for analysis with respectively 78 in the abobotulinum group (group A) and 133 in the onabotulinum group (group O). Neurological conditions were similar between both groups (multiple sclerosis : 29% vs. 32% ; spinal cord injury : 38% vs. 40% ; others : 33% vs. 28% ; p=0.38). Complete success (based on urodynamic and clinical parameters) was obtained in 66% of patients in group O and in 58% of patients in group A (p=0.27). Relief of urinary incontinence was also achievd similarly in both groups (79% vs. 75%; p=0.45). The relative risk of complete success was 0.9 for group O versus group A (IC 95% : 0.7-1.1). Complication rates were very low and similar in both groups (4% vs. 7% ; p=0.37). CONCLUSIONS Detrusor injections of either onabotulinum toxin A or abobotulinum toxin a provides comparable results in the management of NDO. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e36 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Benoit Peyronnet More articles by this author Castel-Lacanal Evelyne More articles by this author Roumiguie Mathieu More articles by this author Marque Philippe More articles by this author Rischmann Pascal More articles by this author Game Xavier More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...